Program
Sodium Nitrite
Also written as “Sodium nitrite”, “AIR-001 SAD dose level 1” and “AIR-001 SAD dose level 2”.
Its studies are mostly in Pulmonary Arterial Hypertension · Subarachnoid Hemorrhage · alpha 1-Antitrypsin Deficiency · COVID-19 · Diabetes Mellitus, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aires Pharmaceuticals | 40 open or running | phase 2since Nov 8, 2012 | Dec 22, 2008 | none ahead |
| Hope Pharmaceuticals | 30 open or running | phase 2since Mar 31, 2009 | Mar 31, 2009 | none ahead |
| TheraVasc | 20 open or running | phase 2since Jun 28, 2011 | Jun 28, 2011 | none ahead |
| AIRNA | 11 open or running | phase 1since Feb 19, 2026 | Feb 19, 2026 | Nov 2028phase 1 · NCT07431112 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2008First study: phase 1 study in Pulmonary Arterial HypertensionNew to Aires PharmaceuticalsAires Pharmaceuticals · NCT00814645 · 25 enrolled · United States
- Mar 31, 2009Hope Pharmaceuticals's first study: phase 2 study in Subarachnoid HemorrhageNew to Hope PharmaceuticalsHope Pharmaceuticals · NCT00873015 · 19 enrolled · United States
- Jun 28, 2011TheraVasc's first study: phase 2 study in Peripheral Arterial DiseaseNew to TheraVascTheraVasc · NCT01401517 · 55 enrolled · United States
- Aug 1, 2011Phase 1 study in Hypertension, PulmonaryAires Pharmaceuticals · NCT01409122 · 42 enrolled · United States
- Nov 8, 20122 phase 2 studies in Pulmonary Arterial HypertensionAires Pharmaceuticals · NCT01725269, NCT01725256
- Feb 19, 2014Phase 2 study in Subarachnoid HemorrhageHope Pharmaceuticals · NCT02176837 · 6 enrolled · United States
- Apr 1, 2015Phase 2 study in Diabetes MellitusTheraVasc · NCT02412852 · 26 enrolled · United States
- May 21, 2020Phase 2 study in COVID-19Hope Pharmaceuticals · NCT04401527 · United States
- Feb 19, 2026AIRNA's first study: phase 1 study in alpha 1-Antitrypsin DeficiencyNew to AIRNAAIRNA · NCT07431112 · 54 planned · Australia, Georgia, Germany and more
Ahead
- Nov 2028Primary completion: phase 1 study in alpha 1-Antitrypsin DeficiencyAIRNA · NCT07431112
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07431112alpha 1-Antitrypsin Deficiency · Australia, Georgia, Germany and more | 1 | Recruiting | AIRNA | Nov 2028 | 54 |
| NCT04401527COVID-19 · United States | 2 | Withdrawn | Hope Pharmaceuticals | Aug 15, 2020 | 0 |
| NCT02412852Diabetes Mellitus · United States | 2 | Completed | TheraVasc | Dec 7, 2015 | 26 |
| NCT02176837Subarachnoid Hemorrhage · United States | 2 | Terminated | Hope Pharmaceuticals | Jan 15, 2017 | 6 |
| NCT01725269Pulmonary Arterial Hypertension · United States, Australia, Hungary | 2 | Terminated | Aires Pharmaceuticals | Apr 2014 | 17 |
| NCT01725256Pulmonary Arterial Hypertension · United States, Australia, Hungary | 2 | Terminated | Aires Pharmaceuticals | Feb 2014 | 29 |
| NCT01409122Hypertension, Pulmonary · United States | 1 | Completed | Aires Pharmaceuticals | Jan 2012 | 42 |
| NCT01401517Peripheral Arterial Disease · United States | 2 | Completed | TheraVasc | Jan 2013 | 55 |
| NCT00873015Subarachnoid Hemorrhage · United States | 2 | Completed | Hope Pharmaceuticals | Nov 2010 | 19 |
| NCT00814645Pulmonary Arterial Hypertension · United States | 1 | Completed | Aires Pharmaceuticals | Apr 2009 | 25 |
How it is read
Names in the registry
- “Sodium Nitrite”, 2 entries
- “Sodium nitrite”, 2 entries
- “AIR-001 SAD dose level 1”, 1 entry
- “AIR-001 SAD dose level 2”, 1 entry
- “AIR-001 SAD dose level 3”, 1 entry
Codes read as this program: AIR001.
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 4 studies
- Subarachnoid Hemorrhage, 2 studies
- alpha 1-Antitrypsin Deficiency, 1 study
- COVID-19, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.